Stocktoria
Vaxcyte, Inc. PCVX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-06-12
Chart by TradingView
1/9
Piotroski F — financial health
7.59
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M |
| Operating cash flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M |
| Free cash flow | -$669.3M | -$475.1M | -$312.9M | -$176.4M | -$127.9M |
| Total assets | $3.0B | $3.5B | $1.4B | $1.0B | $324.3M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M |
| Shareholders' equity | $2.7B | $3.3B | $1.2B | $953.6M | $284.0M |
| Ratios | |||||
| Return on assets | -25.5% | -13.2% | -28.6% | -22.2% | -30.9% |
| Return on equity | -28.5% | -14.0% | -32.4% | -23.4% | -35.2% |
| Current ratio | 7.91 | 12.75 | 7.54 | 23.26 | 8.93 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 620,401 | $36.1M |
| RENAISSANCE TECHNOLOGIES LLC | 54,734 | $3.2M |
| Bridgewater Associates, LP | 12,903 | $749,793 |
| BAUPOST GROUP LLC/MA | 800,000 | $46,488 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 7.59 (safe)
- Working capital / assets 0.473
- Retained earnings / assets -0.718
- EBIT / assets -0.308
- Equity / liabilities 8.466
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001649094 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.